Leptin and adiponectin stimulate the release of proinflammatory cytokines and prostaglandins from human placenta and maternal adipose tissue via nuclear factor-kappaB, peroxisomal proliferator-activated receptor-gamma and extracellularly regulated kinase 1/2.
Beyond their effects on central metabolic functions, leptin, resistin, and adiponectin have profound effects on a number of other physiologic processes, including immune function and inflammation. Although leptin, resistin, and adiponectin are produced in human placenta and adipose tissue, their immunoregulatory actions in these tissues are not known. Therefore, the aim of this study was to determine the effect of leptin, resistin, and adiponectin on the release of proinflammatory mediators in human placenta and sc adipose tissue. Samples were obtained from normal pregnancies at the time of cesarean section. Tissue explants (n = 5) were incubated in the absence (basal control) or presence of a leptin (1, 10, and 100 ng/ml), resistin (1, 10, and 100 ng/ml), and adiponectin (0.1 and 0.5 microg/ml). After 6 h incubation, the medium was collected, and the release of IL-1beta, IL-6, TNFalpha, prostaglandin (PG)F2alpha and PGE2 was quantified by ELISA. There was no effect of resistin on proinflammatory cytokine or prostaglandin release; however, leptin at 100 ng/ml and adiponectin at 0.1 and/or 0.5 microg/ml significantly increased the release of IL-1beta, IL-6, TNFalpha, and PGE2 from human placenta and adipose tissue. Although both leptin and adiponectin significantly increased PGF2alpha release from human placenta, there was no effect of these hormones on PGF2alpha release from adipose tissue. Furthermore, this leptin- and adiponectin-induced proinflammatory response could be abrogated by treatment with the antiinflammatory ERK1/2 MAPK inhibitor U0126, the peroxisomal proliferator-activated receptor-gamma ligand troglitazone, and the nuclear factor-kappaB inhibitor BAY 11-7082. Collectively, these data indicate that leptin and adiponectin activate proinflammatory cytokine release and phospholipid metabolism in human placenta and adipose tissue, and antiinflammatory agents can abrogate leptin- and adiponectin-induced inflammation.
Lappas
Martha
M
Department of Obstetrics and Gynaecology, University of Melbourne and Mercy Perinatal Research Centre, Mercy Hospital for Women, East Melbourne, Victoria, Australia. mlappas@unimelb.edu.au
Permezel
Michael
M
Rice
Gregory E
GE
D052242:Adiponectin; D000273:Adipose Tissue / Q000166:cytology / Q000187:drug effects / Q000502:physiology*; D002470:Cell Survival; D016207:Cytokines / Q000378:metabolism*; D005260:Female; D006729:Hormones, Ectopic / Q000494:pharmacology; D006801:Humans; D007249:Inflammation / Q000503:physiopathology*; D036341:Intercellular Signaling Peptides and Proteins / Q000494:pharmacology*; D020738:Leptin / Q000494:pharmacology*; D019950:Mitogen-Activated Protein Kinase 1 / Q000378:metabolism*; D048052:Mitogen-Activated Protein Kinase 3 / Q000378:metabolism*; D016328:NF-kappa B / Q000378:metabolism*; D009924:Organ Culture Techniques; D047495:PPAR gamma / Q000502:physiology*; D010920:Placenta / Q000166:cytology / Q000187:drug effects / Q000502:physiology*; D011247:Pregnancy; D011453:Prostaglandins / Q000378:metabolism*; D052243:Resistin
D052242:Adiponectin; D016207:Cytokines; D006729:Hormones, Ectopic; D036341:Intercellular Signaling Peptides and Proteins; D020738:Leptin; D016328:NF-kappa B; D047495:PPAR gamma; D011453:Prostaglandins; C499624:RETN protein, human; D052243:Resistin; D019950:Mitogen-Activated Protein Kinase 1; D048052:Mitogen-Activated Protein Kinase 3